Related Experiment Video

Updated: May 24, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

β-blockers in stage B: a precursor of heart failure

Mohammad Sarraf1, Gary S Francis

  • 1Division of Cardiovascular Diseases, University of Minnesota, Variety Club Research Center, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA.

Heart Failure Clinics
|March 13, 2012
PubMed

Insights

Beta-blockers are crucial for treating heart failure (HF), effectively slowing disease progression. They are recommended for patients with asymptomatic left ventricular (LV) dysfunction and are a cornerstone for symptomatic patients with LV systolic dysfunction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Heart failure (HF) management involves addressing left ventricular (LV) dysfunction.
  • Beta-blockers are established treatments for HF.
  • The role of other agents like ivabradine in HF requires clarification.

Purpose of the Study:

  • To review the role of beta-blockers in heart failure treatment.
  • To discuss the application of beta-blockers in different stages of HF.
  • To evaluate the current evidence for beta-blocker therapy in HF.

Main Methods:

  • Literature review of evidence-based guidelines and clinical trials.
  • Analysis of beta-blocker efficacy in symptomatic and asymptomatic LV dysfunction.
  • Assessment of the current evidence for beta-blocker use in Stage B HF.

Main Results:

  • Evidence-based beta-blocker therapy (bisoprolol, carvedilol, metoprolol succinate) is a mainstay for symptomatic LV systolic dysfunction.
  • Beta-blockers should be considered for asymptomatic LV dysfunction.
  • Early introduction of beta-blockers may benefit Stage B HF patients, though large trials are lacking.

Conclusions:

  • Beta-blockers are essential for managing heart failure, particularly LV systolic dysfunction.
  • Consideration of beta-blockers for asymptomatic LV dysfunction is supported.
  • Further research is needed to clarify the role of ivabradine in HF treatment.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...